Literature DB >> 11096478

Neurally Mediated Syncope.

.   

Abstract

Syncope is a common problem in medical practice. Of the various types of syncope, the neurally mediated syncopal syndromes (of which vasovagal syncope is the most common) predominate. In most cases, neurally mediated syncope is a solitary event that can be managed with only reassurance, but certain patients (those with multiple recurrences or those who have been injured as a result of syncope) need further investigation and therapy. Dietary and lifestyle changes are crucial and often overlooked aspects of therapy that may be sufficient to control symptoms. Pharmacologic therapy, which usually starts with beta-blockers or fludrocortisone, can also be effective. Finally, certain patients may continue to have recurrences despite the use of both nonpharmacologic and pharmacologic therapy. It was recently demonstrated that permanent pacing may be effective in preventing recurrent syncopal episodes in some of these patients.

Entities:  

Year:  1999        PMID: 11096478     DOI: 10.1007/s11936-999-0017-5

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  19 in total

1.  Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope.

Authors:  J S Sra; V S Murthy; M R Jazayeri; Y H Shen; P J Troup; B Avitall; M Akhtar
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

2.  The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope.

Authors:  S J Connolly; R Sheldon; R S Roberts; M Gent
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

3.  Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope.

Authors:  W A Scott; G Pongiglione; B I Bromberg; M S Schaffer; B J Deal; F A Fish; M Dick
Journal:  Am J Cardiol       Date:  1995-08-15       Impact factor: 2.778

4.  Tilt training: a new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance.

Authors:  H Ector; T Reybrouck; H Heidbüchel; M Gewillig; F Van de Werf
Journal:  Pacing Clin Electrophysiol       Date:  1998-01       Impact factor: 1.976

5.  Dual chamber pacing aborts vasovagal syncope induced by head-up 60 degrees tilt.

Authors:  A Fitzpatrick; G Theodorakis; R Ahmed; T Williams; R Sutton
Journal:  Pacing Clin Electrophysiol       Date:  1991-01       Impact factor: 1.976

6.  Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope.

Authors:  B P Grubb; D A Wolfe; D Samoil; P Temesy-Armos; H Hahn; L Elliott
Journal:  Pacing Clin Electrophysiol       Date:  1993-03       Impact factor: 1.976

7.  Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia.

Authors:  S Milstein; J Buetikofer; A Dunnigan; D G Benditt; C Gornick; W J Reyes
Journal:  Am J Cardiol       Date:  1990-06-01       Impact factor: 2.778

8.  The use of serotonin reuptake inhibitors for the treatment of recurrent syncope due to carotid sinus hypersensitivity unresponsive to dual chamber cardiac pacing.

Authors:  B P Grubb; D Samoil; D Kosinski; P Temesy-Armos; B Akpunonu
Journal:  Pacing Clin Electrophysiol       Date:  1994-08       Impact factor: 1.976

Review 9.  Cardiac pacing for prevention of recurrent vasovagal syncope.

Authors:  D G Benditt; M Petersen; K G Lurie; B P Grubb; R Sutton
Journal:  Ann Intern Med       Date:  1995-02-01       Impact factor: 25.391

10.  Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results.

Authors:  N Mahanonda; K Bhuripanyo; C Kangkagate; K Wansanit; B Kulchot; K Nademanee; S Chaithiraphan
Journal:  Am Heart J       Date:  1995-12       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.